Sarepta Therapeutics, Inc. SRPT
- Headquarters
- Cambridge, MA
- CEO
- Michael Severino
- Next results
- around Jan 11, 2027
SRPT among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
40 new risk paragraphs. 10-K filed Mar 2, 2026 against Feb 28, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 11 checks found nothing to note
-
Receivables -33.8% ($602.0M to $398.2M) vs revenue +15.6% ($1.9B to $2.2B), -49.4 pts apart
-
Cash from operations −$205.5M vs net income −$713.4M (FY ending Dec 31, 2025)
-
Inventory +22.0% ($750.0M to $914.7M) vs revenue +15.6% ($1.9B to $2.2B), +6.4 pts apart
8 more checks with nothing to note
-
Same auditor in both 10-Ks: KPMG LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Evaluation of lower of cost or net realizable value of raw materials inventory
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
40 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
Further, the current administration has also undertaken significant efforts to reduce the size and spending of the federal government, including at the FDA. A significant reduction in FDA’s workforce or FDA’s budget, or other disruptions at FDA, including any government shutdown, could materially impact FDA’s ability to engage in a…
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
If we or a regulatory agency discover previously unknown adverse events or events of unanticipated severity or frequency, a regulatory agency may establish additional regulatory requirements including, among other things, labeling changes, implementation of risk evaluation and mitigation strategy program, or additional post-marketing…
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
Workforce reductions in and restructuring of the U.S. Department of Health and Human Services, including at the FDA, may also create regulatory uncertainty, potentially impacting drug and biologic development programs and approvals.
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
For example, in March and June 2025, we announced two reported cases of ALF resulting in death in non-ambulatory patients following treatment with ELEVIDYS. Following these announcements, the FDA proposed, and we agreed to, a safety label supplement for ELEVIDYS to include a boxed warning for ALI and ALF. Subsequently, on July 18, 2025…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $933.0M | $1.2B | $1.9B | $2.2B |
| Net income | −$703.5M | −$536.0M | $235.2M | −$713.4M |
| Operating cash flow | −$325.3M | −$501.0M | −$205.8M | −$205.5M |
| Free cash flow | −$356.2M | −$577.1M | −$342.7M | −$307.5M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$2.2B ▲ 15.6% in FY2025−$713.4M in FY2025−$307.5M in FY2025
Recent filings
2 filings in the last 30 days · SEC EDGAR
-
8-KNov 5, 2026Quarterly results 8-K item 2.02
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Sarepta Therapeutics, Inc., Cambridge, MA · from the 10-K filed Mar 2, 2026
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular dystrophy ("Duchenne") and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne and LGMD.
- Headquarters
- Cambridge, MA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 5, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Mar 2, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SRPT/export.csv") into a cell.